Biotech Values

[DewDiligence]

PFE is outperforming the market today to an unusual degree. The only news I’m aware of is that Ranbaxy reported it has taken over the top spot in the US generic-Lipitor market, while PFE’s branded product held the second spot, and WPI’s AG has slipped to a distant third. All this hardly matters, however, insofar as Lipitor’s Hatch-Waxman six-month exclusivity period expires in a few weeks.